Abstract: Exposure to acute psychological or physical stress increases core body temperature (stress-induced hyperthermia, SIH) which is part of the autonomic stress response. SIH is used as a putative rodent anxiety paradigm in which anxiolytic drugs reduce the SIH response. The predictive validity of the SIH paradigm has proven to be good, making it suitable to detect the putative anxiolytic properties of drugs. So far, GABA A receptor agonists including benzodiazepines and hypnotics have proven to attenuate the SIH response. The GABA A receptor has been known to be closely involved in the acute stress response. Also, the recent development of compounds with selective efficacy for different subunits at the benzodiazepine site of the GABA A receptor has renewed interest for the therapeutic potential of GABAergic drugs. Moreover, metabotropic (GABA B ) receptor agonists reduce the SIH response. GABA B receptors are ubiquitously expressed in the central nervous system, and there is evidence for a role of the GABA B receptor in anxiety. Thus, both drugs acting on the GABA A and the GABA B receptor are generally able to attenuate the SIH response, and this review presents a detailed overview of the effects of both drug classes on the SIH response. As the GABA receptor family is diverse and complex, this paradigm may contribute to the elucidation of the putative effects of GABAergic drugs in emotional disorders such as anxiety and depression Keywords: Model, drug screening, emotional fever, ionotropic, TP003, TPA023, zolpidem, zopiclone.
THE SIH PARADIGM
Exposure to acute psychological or physical stress robustly increases core body temperature (stress-induced hyperthermia, SIH) which is part of the autonomic stress response [1] . The fact that perceived stressful occasions (e.g. during a movie or prior to a sporting contest) increase body temperature in humans has been known for a long time [2, 3] . However, it was not until decades later that the SIH response was used as a putative rodent anxiety test when it was noticed that removing mice one by one from a grouphoused cage reproducibly increased body temperature of the last mouse compared to the first [4] . Later, this putative anticipatory anxiety test was improved to a singly-housed version in which the rectal temperatures are measured twice with an interval of 10 minutes (representing basal and stressed temperature values) [5] . More recently, the advent of telemetric systems that can accurately measure body temperature have led to increasing application of such systems in SIH experiments [6, 7] .
The predictive validity of the SIH paradigm has proven to be good, making it suitable to screen putative anxiolytic drugs [1] . So far, drugs with anxiolytic properties such as GABA A receptor and 5-HT 1A receptor agonists as well as CRF receptor antagonists have proven to attenuate the SIH response, whereas non-anxiolytic dopaminergic or noradrenergic drugs generally do not affect the SIH response [8] . Moreover, acute administration of selective serotonin reuptake inhibitors and tricyclic antidepressants have no effect on the SIH response [8] . So far, chronic treatment with antidepressants has not resulted in altered SIH responses either.
Ionotropic (GABA A ) and metabotropic (GABA B ) receptors are ubiquitously expressed in the central nervous system [9, 10] . The GABA A receptor (GABA A R) has been known to be closely involved in the acute stress response and clinically relevant anxiolytic drugs such as benzodiazepines act on this receptor [11] , whereas evidence for a role of the GABA B receptor in anxiety has more recently accumulated [12, 13] . Both drugs acting on the GABA A and the GABA B receptor are generally able to attenuate the SIH response, and this review therefore presents a detailed overview on the effects of both drug classes in the SIH paradigm. SIH is an unconditioned, consistent and robust response, and the SIH test is easy to perform in acute and chronic setups. Moreover, the SIH paradigm is able to measure the effects of anxiolytic drugs on the SIH response as well as basal body temperature. As the GABA receptor family is diverse and complex, this model may contribute to the elucidation of the putative effects of GABAergic drugs in emotional disorders such as anxiety and depression.
THE GABA A RECEPTOR
GABA A Rs are ligand-gated ion channels that mediate fast inhibitory effects and are ubiquitously present in the central nervous system (Fig. 1) , even though a typical central subunit distribution seems to exist [9, 14] . When GABA binds, chloride ions flow into the neuron, resulting in a hyperpolarization of the cell membrane. GABA A Rs are found synaptically as well as extrasynaptically and are composed of five subunits with various possibilities per subunit ( 1-6 , 1-3 , 1-3 , , , and ) that assemble to form a pentameric ligand-gated chloride channel. The GABA A R displays a large molecular heterogeneity that depends on a variable subunit composition which ultimately determines physiological and pharmacological receptor properties and contributes to flexibility in signal transduction and modulation [11] . The most common subtype is a pentamer with 2 , 2 and 1 subunit [15] . The fact that two different subunits can co-exist in a single GABAA receptor adds to the variability of this receptor [16] . Different classes of pharmacological agents act on different sites on the GABA A R. Classic benzodiazepines bind to the GABA A R benzodiazepine modulatory site between the and subunit. Other drug classes also bind to the GABA A R, such as alcohol, barbiturates and neurosteroids [17] . Classical (non-selective) benzodiazepines allosterically enhance the inhibitory actions of GABA by binding to GABA A Rs that contain 1 , 2 , 3 or 5 subunits in combination with a and a 2 subunit. Recently, genetic and pharmacological evidence has indicated that subunits may differentially contribute to the various classical benzodiazepines effects such as anxiolysis, dependence, anticonvulsant activity, sedation and amnesia [18, 19] . More specifically, the 1 subunit (present in over 50% of all GABA A Rs) is thought to mediate the sedative and amnestic actions of benzodiazepines, whereas 2 and 3 subunits (present in 10-20% of all GABA A Rs) probably mediate the anxiolytic action of benzodiazepines [20] [21] [22] . GABA A R 2 and 3 subunit involvement in the anxiolytic effects of benzodiazepines is derived from studies of knock-in mice that point to a role for the 2 subunit, whereas pharmacological experiments suggest a role for the 3 subunit. Currently, there is no good explanation for these apparent discrepancies.
The development of compounds with contrasting binding affinities for all subunits has proven to be difficult as the benzodiazepine binding site is probably highly conserved between different subunits. Thus, compounds that are affinity-selective in vitro are generally less or even nonselective in vivo, and finding compounds with differential subunit affinity is a difficult goal to achieve. More recently, an alternative approach resulted in the development of compounds with selective efficacy for different subunits of the GABA A R. Such drugs generally bind with equal affinity to all subunits, but selectively modulate the activity of one or some of them (Fig. 2) . Already earlier, partial agonists with lower efficacy at the GABA A R compared to classical benzodiazepines such as bretazenil and abecarnil were developed. These drugs display overall lower efficacy at all subunits and were thought to have decreased side effects, but resulted in severe sedation in humans [23] . Moreover, in contrast to the GABA A R subtype specificity hypothesis, recently developed compounds with more 1 agonistic activity compared to the 2 , 3 and 5 subunit appeared to be anxioselective in humans, indicating that the preclinical profile of GABA A ergic compounds does not always predict the clinical effects [24, 25] . A possible explanation for these results could be that compounds only need moderate efficacy at 2 subunits to produce anxiolysis, whereas high efficacy at 1 subunits is required for sedation. However, these results show that GABA A R pharmacology is complex and not fully understood. The concept that distinct GABA A R subtypes generate the various clinical benzodiazepine effects remains valuable, and research on the GABA A R in stress and anxiety processes therefore presents opportunities for the development of novel anxiolytic compounds.
In addition to the efforts that have been made on compounds targeting the GABA A R subunits, the subunit has also proven to influence benzodiazepine efficacy as the benzodiazepines binding site is located between the and the subunit [18] . Interestingly, exchanging the abundant 2 subunit for a 3 subunit resulted in decreased benzodiazepine affinity, whereas the hypnotic CL218,872 (with 17-fold selectivity for the 1 subunit [26] ) displayed an increased affinity [27] . This suggests that a compound with x 3 affinity over x 2 affinity may constitute a novel target for the development of hypnotic or anxiolytic drugs.
In summary, the search for new anxiolytic drugs has focused on subunit specific GABA A R agonists as such drugs are expected to dissociate anxiolytic from sedative effects. Prime candidates for non-sedating anxiolytic drugs appear to be compounds that lack activity at the 1 -containing GABA A R while modulating the 2 and/or 3 GABA A R subunit. These compounds could exert anxiolytic effects, whereas side effects which currently limit benzodiazepine use (among which sedation, ataxia, amnesia, alcohol potentiation, tolerance development and abuse potential) would be absent. Fig. (2) . Schematic summary of the GABA-enhancing properties (% GABA response) of a fictional benzodiazepine-like compound with a reduced affinity for GABA A receptor subtype 2 and a reduced efficacy at GABA A receptor subtype 3 compared to subtype 1.
THE GABA B RECEPTOR
The GABA B receptor is a G-protein coupled receptor consisting of a heterodimer made up of two subunits, GABA B(1) and GABA B(2), both of which are necessary for GABA B receptors to be functionally active [28] (Fig. 3) . They are expressed both as presynaptic heteroreceptors and also postsynaptically, where they respectively modulate neuronal excitability. Heteroreceptors modulate the release of (excitatory) neurotransmitters, mainly via actions on presynaptic Ca +2 channels, and postsynaptic GABA B receptors activate slow inhibitory postsynaptic potentials via activation of inwardly-rectifying K + channels. GABA B receptors also function as autoreceptors on interneurons. Additionally, GABA B receptors are negatively coupled to adenylyl cyclase, through which they influence downstream molecular pathways [29] .
There is a growing body of evidence indicating that GABA B receptors play a critical role in anxiety [30] . The prototypical GABA B receptor agonist, baclofen, has shown anxiolytic activity in some clinical settings. Baclofen reduced anxiety in post-traumatic stress disorder (PTSD) patients [31] , in alcoholics following alcohol withdrawal [32, 33] , in panic disorder [34] and in patients suffering from acute spinal trauma [35] . Baclofen has also demonstrated anxiolytic effects in several preclinical studies including ultrasonic vocalisation in rat pups [36] , increased punished drinking [37] , elevated plus maze [38] (but see [39] ) and in the social interaction and elevated plus maze tests following withdrawal of dependent rats from either diazepam or alcohol [40] [41] [42] .
Perhaps the strongest preclinical evidence to date for a role of GABA B receptors in anxiety was demonstrated by the phenotype of GABA B receptor-deficient mice. Deletion of either the GABA B(1) or GABA B(2) receptor subunits results in a complete loss of typical GABA B functions and induces a highly anxious phenotype in mice in exploratory-based tests of anxiety [43, 44] . Furthermore, the GABA B(1) subunit is predominantly expressed as one of two isoforms: GABA B(1a) or GABA B(1b) , and deletion of these isoforms has differential effects on the acquisition and extinction of amygdala dependent conditioned aversive learning tasks [45] .
Although studies with the GABA B receptor agonist, baclofen, have supported a role for GABA B receptors in anxiety its hypothermic, sedative and muscle-relaxant profile in a wide range of different species limit its applicability as a tool for behavioural research and as a therapy in psychiatry [29, 30, 46] . Recently, positive modulators of the GABA B receptor have been developed. CGP7930 and its aldehyde analogue CGP13501 were the first GABA B receptor positive modulators to be characterised in vitro [47] . A subsequent, structurally distinct chemical series which includes the more efficacious GS39783 were published shortly thereafter [48] . More recently two new classes have been identified rac-BHFF [49] and BHF177 [50, 51] . All of these compounds enhance both the potency and the maximal efficacy of GABA at GABA B receptors in vitro, via interactions with the 7-transmembrane domain of the GABA B(2) subunit, although they have little to no intrinsic action by themselves [13, 52] . CGP7930, rac-BHFF and GS39783 have also demonstrated GABA B receptor positive modulation properties in vivo. CGP7930 and rac-BHF177 potentiated the loss-of righting effects of the GABA B receptor agonists baclofen and gamma-hydroxybutyrate (GHB) [49, 53] , while in a microdialysis study, GS39783 potentiated the inhibitory effects of baclofen on forskolin-induced cAMP production in the rat striatum [54] . Of particular note, GABA B receptor positive modulators demonstrated anxiolytic profile in multiple rodent tests [13, 49] without showing the motor impairing hypothermic or cognitive impairing actions that are characteristic of full GABA B receptor agonists [13, 43, 55] .
EFFECTS OF GABA A ERGIC DRUGS ON THE SIH RESPONSE

Benzodiazepine Site Ligands
Classical Benzodiazepines
Classical benzodiazepines (among which chlordiazepoxide, diazepam, oxazepam, nitrazepam and alprazolam) dose-dependently reduce the SIH response, and, at higher doses, also reduce basal body temperature in rodents [1, 8] . So far, all benzodiazepines that have been studied in the original group-housed and the singly-housed SIH paradigm reduce the SIH response ( as a positive reference compound [56] [57] [58] . A typical example of the effects of the classical benzodiazepine diazepam on the SIH response in mice is shown in Fig. (4A) . The SIH response is significantly decreased in drug-treated mice compared to vehicle-treated animals (one-way ANOVA with T 1 and T 2 as within-subject factor (SIH) and treatment as between-subject factor, diazepam x SIH interaction F 2,26 =3.27, p<0.05). Moreover, diazepam significantly reduced basal body temperature at both doses (main diazepam effect F 1,26 =15.67, p<0.001 with Dunnett's multiple comparison as post-hoc test). As classical benzodiazepines bind to 1 , 2 , 3 and 5 subunits [59, 60] , their effects on both the SIH response and basal body temperature are mediated via these subunits. Flumazenil (Ro 15-1788), a silent non-selective GABA A R subunit antagonist, dose-dependently reversed the diazepam effects on the SIH response and basal body temperature in mice [61] . This illustrates the close involvement of the GABA A R subunit in the benzodiazepine action on the SIH response as repeatedly has been shown that flumazenil does not influence the SIH response or basal body temperature levels [61] [62] [63] .
Benzodiazepine Agonists
If GABA A R subunits indeed differentially contribute to the various effects of classical benzodiazepines, the question remains how more selective drugs for these GABA A R subtypes influence the SIH response and body temperature. So far, a number of drugs with subtype selective activity have been tested in the SIH paradigm (Table 3) . Zolpidem, with 5-10 fold more selectivity for 1 subunits compared to 2 / 3 subunits [64] , generally causes hypothermia without attenuating of the SIH response, indicating that the GABA A R 1 subunit is not directly involved in anxiolytic effects but plays a role in thermoregulatory processes. In rats, zolpidem reduced the SIH response, but this was most likely the result of strong hypothermic effects on basal body temperature that disturbed physiological homeostatic mechanisms [65] . The hypothermic effects of zolpidem in mice are illustrated in Zolpidem also affected the SIH response (zolpidem x SIH interaction F 4,72 =27.81, p<0.001). The apparent increase of the SIH response at lower doses is caused by a general body temperature reduction, allowing the SIH response to increase as the maximum body temperature is limited due to ceiling effects. At the highest dose, the reduction of the SIH response can be explained by the strong hypothermic and not necessarily anxiolytic effects of zolpidem. However, zolpidem may demonstrate less 1 subunit selectivity in vivo compared to in vitro studies using recombinant receptors, and it is possible that zolpidem may exert anxiolytic effects and reduce the SIH response in vivo via 2/3 subunits [66] . L838,417 is a compound with comparable affinity for the 1,2,3,5 subunits, but with no efficacy at the 1 subtype and partial agonistic efficacy at 2 , 3 and 5 subtypes [21] . In three different mouse strains, L838,417 dose-dependently reduced the SIH response without affecting basal body temperature [63] , indicating that the SIH response and basal body temperature can be independently altered depending on the drug properties. A putative role for the GABA A R 3 subunit in the SIH response anxiety was confirmed using the GABA A R 3 subunit agonist TP003 that attenuated the SIH response without affecting basal body temperature levels in both rats and mice [20, 65] . Recently, we tested an essentially 5 selective compound which neither affected the SIH response nor caused hypothermia (unpublished data). This confirmed that activation of the 5 subunit is not essential for anxiolytic effects of classical benzodiazepines. There is increasing evidence for a role of the 5 subunit in cognitive processes however [67] , and as a result, inverse 5 subunit agonists are being developed as cognition enhancers [68] . The low efficacy positive GABA A R modulator bretazenil was found to be ineffective in the SIH paradigm in NMRI mice [61] . The marginal effects of bretazenil on either the SIH response or basal body temperatures were confirmed in 129Sv/Ev mice (main bretazenil effect F 3,61 =0.82, p=0.49, NS, Fig. 4C) . Interestingly, bretazenil significantly reduced the SIH response in this strain (bretazenil x SIH interaction F 3,61. =2.70, p=0.05). These results are in line with previous research that showed an excellent non-sedating preclinical profile for this drug [69] , even though later clinical studies showed that bretazenil caused sedation [23] .
Benzodiazepine Antagonists
Based on these results, we hypothesize that the 2 and/or the 3 GABA A R subunit is involved in the attenuation of the SIH response, whereas GABA A R 1 subunit activation results in hypothermia. If hypothermia and sedation are both the result of GABA A R 1 subunit activation, an absence of lower body temperatures after drug administration may indicate reduced sedative side effects. To test this hypothesis, we combined the classical benzodiazepine diazepam and the hypnotic zolpidem with the 1 subunit antagonist CCt in rats [65] (Table 2) . CCt is a compound with high affinity for the GABA A receptor 1 subunit compared to the 2 , 3 , and 4 subunits and with comparable low efficacy at all subunits [70] . We found that administration of CCt alone had no effect on either basal body temperature or novel cage-induced temperatures. However, prior injection with CCt antagonized hypothermic effects of both diazepam and zolpidem. We replicated this finding in mice (Fig. 4D, unpublished results) 
Inverse Benzodiazepine Agonists
Recently, we showed that the inverse benzodiazepine agonist F7142 indeed resulted in hypothermia in rats, although only a high dose (15 mg/kg) was used (Fig. 5,  unpublished results) . However, acute administration of the inverse benzodiazepine agonists pentylenetrazole and FG-7142 did not result in an increased SIH response (Table 3) .
Inverse benzodiazepine agonists allosterically decrease the binding of GABA and negatively influence constitutive GABA A R activity. These compounds display anxiogenic effects in various animal models of anxiety [71, 72] . Putative anxiogenic drugs generally do not increase the autonomic SIH response in preclinical studies, suggesting that increased anxiety levels are not automatically accompanied by higher autonomic stress responsivity. Although anxiogenic compounds are considered to heighten subjective anxiety levels, tachycardia in anxious people depends on the situation and diagnosis, and a more avoiding personality is associated with reduced heart rate responses [73] . Moreover, patients with panic disorder (PD) display comparable physiological responses to healthy controls, even though they experience more frequent distress, suggesting that the perception of stress in anxiety disorders is not accompanied by heightened autonomic responses [74] . Increased subjective stress levels due to anxiogenic drugs may not necessarily be accompanied by increased autonomic stress responsivity, which is in line with the SIH literature so far. Alternatively, the fact that stress-induced body temperatures display a consistent maximum value above which stress does not further increase body temperature may explain why the SIH model is less appropriate for the screening of anxiogenic properties of drugs. Moreover, bimodal influences of inverse benzodiazepines on locomotor responses have been described [77] . Therefore, inverse benzodiazepine agonists may exert increased hyperthermia or hypothermia as well depending on the dose. Further research with subunit preferential inverse benzodiazepine agonists (such as 3IA [71] ) is needed to elucidate the exact effects of inverse benzodiazepine agonists in the SIH model. 
Other Drugs Binding to the GABA A Receptor
Alcohol
The GABA A R has been implicated in the anxiolytic effects of alcohol. Generally, alcohol is thought to affect the tonic inhibition generated by extrasynaptic GABA A Rs that contain 4 , 6 and subunits [78] , whereas modulation of synaptic GABA A Rs is only present at higher concentrations [79] . However, alcohol also enhances inhibition via a GABA A ergic presynaptic mechanism in various brain areas including the amygdala [80] . At higher doses, alcohol can also modulate excitatory N-methyl-D-aspartic acid (NMDA) and non-NMDA glutamate receptors, serotonin and glycine receptors, as well as potassium and calcium channels [81, 82] In the SIH model, alcohol consistently decreases the SIH response in rats as well as mice, although the effects on basal body temperature appear strain dependent (Table 5 ). In Fig.  (6A) , a typical example of the effects of alcohol on the SIH response is shown. Here, alcohol reduced the SIH response (alcohol x SIH interaction, F 3,72 =8.58, p<0.001), whereas it reduced the basal body temperature at the highest dose (main alcohol effect, F 3,72 =10.28, p<0.001, with Dunnett's multiple comparison as post-hoc test). Although acute administration of alcohol is known to possess an anxiolytic profile, these effects are not identical to those of classic benzodiazepines [83] . The question remains whether this putative anxiolytic alcohol effect is mediated by synaptic or extrasynaptic GABA A R activation. The fact that -subunit deficient mice demonstrate a normal anxiolytic and hypothermic response to alcohol suggests that the discussion on the (exra)synaptic mechanism by which alcohol activates the GABA A R is ongoing [84] .
Compounds Acting on the GABA Binding Site
Endogenous GABA can bind at two different GABA binding sites located between the and GABA A R subunits [95, 96] . Exogenous compounds that can bind to the same binding sites include agonists muscimol and gaboxadol as well as the antagonist bicuculline [97] . Endogenous and exogenous ligands have different affinity for the two GABA binding sites as one GABA binding site is flanked by a and a subunit and the other by an and a subunit [98] (Fig.  1) .
Drugs that directly act on the GABA binding site have received limited attention in the SIH model. The putative anxiolytic drug gaboxadol (THIP) has a high efficacy at extrasynaptic receptors compared to GABA [99, 100] . The subunit-containing GABA A R are often located extrasynaptically and perisynaptically and are thought to be involved in a continuous active inhibitory tone instead of the phasic inhibitory tone caused by intrasynaptic agonists [101, 102] . In rats, gaboxadol reduced basal body temperature and the SIH response only at the highest dose tested (10 mg/ kg), whereas lower doses were ineffective [65] . The GABA binding site agonist muscimol dose-dependently reduced basal body temperature (Fig. 6B, main muscimol 43 ,=1.13, p=0.35, NS), although an increased body temperature at the highest dose is apparent (Fig. 6C,  unpublished results) . Overall, for drugs acting at the GABA site, it seems likely that, at higher doses, agonists cause hypothermia whereas antagonists increase basal body temperature. The SIH response is generally unaffected except at high doses when interference with physiological thermoregulation occurs. So far, no clear anxiolytic effects of drugs acting at the GABA binding site have been found in the SIH model.
Neurosteroids, Barbiturates and General Anesthetics
Neurosteroids are strong and rapid potentiators of GABA A Rs, interacting with more than one steroid-binding site [103, 104] . Recently, the GABA A R 1 subunit was found to be essential for the response to neurosteroids [105] . This generic pharmacological profile of neurosteroids is ascribed to a highly conserved amino acid (glutamine, Q241) in the GABA A R subunits [106] . However, neursteroids have an increased potency at the 5 subunit [107] and extrasynaptic subunit-containing GABA A R receptors [108] . No neurosteroids have been tested in the SIH model yet. The putative anxiolytic effects of neurosteroids in other studies suggest that these drugs might be effective in the SIH model [109, 110] .
Barbiturates bind to the GABA A R at the subunit with distinct binding sites from the GABA and the benzodiazepine binding site [17] . Two studies found that phenobarbital was able to reduce the SIH response in mice, whereas another study that used higher doses did not find any effects (Table 5) . At lower doses, barbiturates enhance GABA binding, although it potentiates GABA A Rs at moderate doses in the absence of GABA, and even block GABA A Rs at high doses [111] . Therefore, the anxiolytic effects of phenobarbital on the SIH response may depend on the applied dose. GABA A R-sensitive general anesthetics such as etomidate and propofol cause unconsciousness and immobility by acting on extrasynaptic tonic inhibitory 4/6 3 and 4 3 GABA A Rs [112] . No anxiolytic properties have been ascribed to general anesthetics, and, to our knowledge, these compounds have not been applied in the SIH model.
EFFECTS OF GABA B ERGIC DRUGS ON THE SIH RESPONSE
Baclofen's effects on SIH have been assessed [86] . These studies show little anxiolytic effects at doses that do not alter baseline temperature. Given the ability of full GABA B receptor agonists to produce dose-dependent mechanisticallypredicted temperature decreases [46] it is unlikely that the SIH paradigm will be sensitive enough to dissociate baseline changes in homeostatic physiology with the potential ability of full agonists to reverse stress-induced autonomic responses. Similar problems also lie with assessing the effects of other classes of ligands such as nicotine (see [8] for discussion) or certain GABA A R ligands (see above; and [6]. The development of GABA B receptor positive modulators, which on the whole have no intrinsic effects on temperature, has allowed for the contribution of GABA B receptors to the SIH response to be better elaborated (Table 6) .
Initial studies characterized the effects of GS39783 on SIH where it was demonstrated that at oral doses from 0.1 -30 mg/kg. GS39783 was able to counteract the SIH response [13] although the effect size was less than that garnered with benzodiazepines. The effects of CGP7930 on SIH were also demonstrated but these were less potent than chlordiazepoxide and that previously shown for GS39783, with only the 100 mg/kg dose effective [55] . Interestingly, the magnitude of the effect was relatively similar between both GABA B receptor modulators. Recent studies with the novel modulator rac-BHFF (doses 3, 10, 30 and 100mg/kg, p.o.) demonstrated anxiolytic effects at all doses but with significance reached for 100 mg/kg dose only [49] .
Preliminary data demonstrates that BHF177 at oral doses of 20 and 30 mg/kg displayed an anxiolytic-like SIH test in mice [50] . However, given that BHF177, at doses over 40 mg/kg caused hypothermia -distinct from the lack of effect of other GABA B receptor positive modulators on temperature -the observed anxiolytic property in the SIH Fig. (6) . Effects of GABA A receptor modulator alcohol (A), GABA A receptor GABA site agonist muscimol (B) and GABA A receptor GABA site antagonist bicucculine (C) on the SIH response in 129Sv/Ev mice (n=10-16). *: p<0.05; **: p<0.01; ***: p<0.001.
test must be viewed with caution and such effects requires further confirmation in paradigms not reliant on body temperature.
CONCLUSION
A wide variety of GABA A ergic compounds have been applied using the SIH paradigm, and there is overwhelming evidence that classical benzodiazepines dose-dependently reduce the SIH response. Subsequent studies that have applied GABA A subunit selective compounds as well as combination of agonists and antagonists have confirmed a role for the GABA A R 2/3 subunit in the reduction of the SIH response (anxiolytic effect), whereas the GABA A R 1 subunit primarily causes hypothermia. Thus, the effects of Although baseline temperature effects of GABA B receptor agonists preclude the drawing of any decisive conclusions on the role of this receptor in SIH, the development of novel GABA B receptor positive modulators does indeed suggest that this receptor is a novel mechanism for counteracting SIH. To date, all of the four classes of modulators have been able to significantly counteract SIH and this paradigm is ideal for assessing the anxiolytic potential of future GABA B receptor modulators.
In conclusion, the SIH paradigm appears to be sensitive to detect the putative anxiolytic effects of GABAergic compounds acting on the GABA A and GABA B receptors in the central nervous system. 
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